Research ExplorerPublicationsIxekizumab treatment and the impact on SF-36: results from t...

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

Standard

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. / Langley, Richard G B; Reich, Kristian; Strand, Vibeke; Feldman, Steven R; Paul, Carle; Gordon, Kenneth; Warren, Richard B; Toth, Darryl; Nikaï, Enkeleida; Zhu, Baojin; Goldblum, Orin; Edson-Heredia, Emily; Carlier, Hilde; Burge, Russel; Lin, Chen-Yen; Hollister, Kristin; Augustin, Matthias.

In: QUAL LIFE RES, Vol. 29, No. 2, 02.2020, p. 369-380.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Langley, RGB, Reich, K, Strand, V, Feldman, SR, Paul, C, Gordon, K, Warren, RB, Toth, D, Nikaï, E, Zhu, B, Goldblum, O, Edson-Heredia, E, Carlier, H, Burge, R, Lin, C-Y, Hollister, K & Augustin, M 2020, 'Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis', QUAL LIFE RES, vol. 29, no. 2, pp. 369-380. https://doi.org/10.1007/s11136-019-02296-5

APA

Langley, R. G. B., Reich, K., Strand, V., Feldman, S. R., Paul, C., Gordon, K., Warren, R. B., Toth, D., Nikaï, E., Zhu, B., Goldblum, O., Edson-Heredia, E., Carlier, H., Burge, R., Lin, C-Y., Hollister, K., & Augustin, M. (2020). Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. QUAL LIFE RES, 29(2), 369-380. https://doi.org/10.1007/s11136-019-02296-5

Vancouver

Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K et al. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. QUAL LIFE RES. 2020 Feb;29(2):369-380. https://doi.org/10.1007/s11136-019-02296-5

Bibtex

@article{79132adce160468c846e1a0eb6af590f,
title = "Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis",
abstract = "PURPOSE: To assess improvements in health-related quality of life (HRQoL) with ixekizumab treatment in patients with moderate-to-severe psoriasis.METHODS: Adults with plaque psoriasis were enrolled in phase III, double-blind, randomised, controlled trials (UNCOVER-1, UNCOVER-2, or UNCOVER-3). All 3 protocols included a 12-week, placebo-controlled induction period; UNCOVER-2 and UNCOVER-3 also had an active-control group (50 mg etanercept) during induction. After induction, patients in UNCOVER-1 and UNCOVER-2 entered a 48-week withdrawal (maintenance) period (Weeks 12-60), during which Week-12 sPGA (0,1) responders were rerandomized to receive placebo, or 80 mg ixekizumab every 4 weeks (Q4W) or 12 weeks. As a secondary objective, HRQoL was measured by the generic Medical Outcomes Survey Short Form-36 (SF-36) at baseline and Weeks 12 and 60. Changes in mean SF-36 Physical and Mental Component Summary (PCS and MCS) and domain scores and proportions of patients reporting improvements ≥ minimal important differences in SF-36 scores were compared between groups.RESULTS: At Week 12, ixekizumab-treated patients (both dose groups in UNCOVER-1, -2, and -3) reported statistically significantly greater improvements in mean SF-36 PCS and MCS and all 8 SF-36 domain scores versus placebo. Further, more ixekizumab-treated patients than placebo-treated patients reported at least minimal treatment responses in SF-36 PCS and MCS scores and domain scores. Overall improvements in SF-36 PCS and MCS scores were maintained through Week 60.CONCLUSIONS: Ixekizumab-treated patients reported statistically significant improvements in HRQoL at 12 weeks that persisted through 1 year.",
author = "Langley, {Richard G B} and Kristian Reich and Vibeke Strand and Feldman, {Steven R} and Carle Paul and Kenneth Gordon and Warren, {Richard B} and Darryl Toth and Enkeleida Nika{\"i} and Baojin Zhu and Orin Goldblum and Emily Edson-Heredia and Hilde Carlier and Russel Burge and Chen-Yen Lin and Kristin Hollister and Matthias Augustin",
year = "2020",
month = feb,
doi = "10.1007/s11136-019-02296-5",
language = "English",
volume = "29",
pages = "369--380",
journal = "QUAL LIFE RES",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "2",

}

RIS

TY - JOUR

T1 - Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

AU - Langley, Richard G B

AU - Reich, Kristian

AU - Strand, Vibeke

AU - Feldman, Steven R

AU - Paul, Carle

AU - Gordon, Kenneth

AU - Warren, Richard B

AU - Toth, Darryl

AU - Nikaï, Enkeleida

AU - Zhu, Baojin

AU - Goldblum, Orin

AU - Edson-Heredia, Emily

AU - Carlier, Hilde

AU - Burge, Russel

AU - Lin, Chen-Yen

AU - Hollister, Kristin

AU - Augustin, Matthias

PY - 2020/2

Y1 - 2020/2

N2 - PURPOSE: To assess improvements in health-related quality of life (HRQoL) with ixekizumab treatment in patients with moderate-to-severe psoriasis.METHODS: Adults with plaque psoriasis were enrolled in phase III, double-blind, randomised, controlled trials (UNCOVER-1, UNCOVER-2, or UNCOVER-3). All 3 protocols included a 12-week, placebo-controlled induction period; UNCOVER-2 and UNCOVER-3 also had an active-control group (50 mg etanercept) during induction. After induction, patients in UNCOVER-1 and UNCOVER-2 entered a 48-week withdrawal (maintenance) period (Weeks 12-60), during which Week-12 sPGA (0,1) responders were rerandomized to receive placebo, or 80 mg ixekizumab every 4 weeks (Q4W) or 12 weeks. As a secondary objective, HRQoL was measured by the generic Medical Outcomes Survey Short Form-36 (SF-36) at baseline and Weeks 12 and 60. Changes in mean SF-36 Physical and Mental Component Summary (PCS and MCS) and domain scores and proportions of patients reporting improvements ≥ minimal important differences in SF-36 scores were compared between groups.RESULTS: At Week 12, ixekizumab-treated patients (both dose groups in UNCOVER-1, -2, and -3) reported statistically significantly greater improvements in mean SF-36 PCS and MCS and all 8 SF-36 domain scores versus placebo. Further, more ixekizumab-treated patients than placebo-treated patients reported at least minimal treatment responses in SF-36 PCS and MCS scores and domain scores. Overall improvements in SF-36 PCS and MCS scores were maintained through Week 60.CONCLUSIONS: Ixekizumab-treated patients reported statistically significant improvements in HRQoL at 12 weeks that persisted through 1 year.

AB - PURPOSE: To assess improvements in health-related quality of life (HRQoL) with ixekizumab treatment in patients with moderate-to-severe psoriasis.METHODS: Adults with plaque psoriasis were enrolled in phase III, double-blind, randomised, controlled trials (UNCOVER-1, UNCOVER-2, or UNCOVER-3). All 3 protocols included a 12-week, placebo-controlled induction period; UNCOVER-2 and UNCOVER-3 also had an active-control group (50 mg etanercept) during induction. After induction, patients in UNCOVER-1 and UNCOVER-2 entered a 48-week withdrawal (maintenance) period (Weeks 12-60), during which Week-12 sPGA (0,1) responders were rerandomized to receive placebo, or 80 mg ixekizumab every 4 weeks (Q4W) or 12 weeks. As a secondary objective, HRQoL was measured by the generic Medical Outcomes Survey Short Form-36 (SF-36) at baseline and Weeks 12 and 60. Changes in mean SF-36 Physical and Mental Component Summary (PCS and MCS) and domain scores and proportions of patients reporting improvements ≥ minimal important differences in SF-36 scores were compared between groups.RESULTS: At Week 12, ixekizumab-treated patients (both dose groups in UNCOVER-1, -2, and -3) reported statistically significantly greater improvements in mean SF-36 PCS and MCS and all 8 SF-36 domain scores versus placebo. Further, more ixekizumab-treated patients than placebo-treated patients reported at least minimal treatment responses in SF-36 PCS and MCS scores and domain scores. Overall improvements in SF-36 PCS and MCS scores were maintained through Week 60.CONCLUSIONS: Ixekizumab-treated patients reported statistically significant improvements in HRQoL at 12 weeks that persisted through 1 year.

U2 - 10.1007/s11136-019-02296-5

DO - 10.1007/s11136-019-02296-5

M3 - SCORING: Journal article

C2 - 31655974

VL - 29

SP - 369

EP - 380

JO - QUAL LIFE RES

JF - QUAL LIFE RES

SN - 0962-9343

IS - 2

ER -